ADO 0.00% 2.1¢ anteotech ltd

Luminex Partner Trial Completion?, page-5

  1. 1,087 Posts.
    I daresay, any deal with Luminex will be overwhelming in PR and underwhelming in revenue, similar to deals with Banglabs, Merck, Ebioscience and Affymetrix.
    All evidence points to the fact that this technology is not disrupting at all.
    getting a drug through to a phase 3 clinical trial would be quicker in it's progress
    It may have a niche but nothing to justify the present market cap.
 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.